MDM2 and cancer: Also, targeting NRP1 as a means to enter cancer cells is the work developed by Zhou et al. The development of a D-peptide that targets this overexpressed receptor on cancer cells as well as MDM2 has demonstrated strong anticancer activity to liver cancer cells in vitro and in vivo, with no apparent host toxicity [196].